Le Lézard
Classified in: Health, Science and technology
Subject: CCA

Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets


SAN FRANCISCO, May 2, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through June 9, 2024.

To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.

About Nektar Therapeutics

Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow us on LinkedIn.

Contacts:

For Investors:                                                                                             

Vivian Wu of Nektar Therapeutics

(628) 895-0661

For Media:

David Rosen of Argot Partners

(212) 600-1902

[email protected]

SOURCE Nektar Therapeutics


These press releases may also interest you

at 08:17
Global Landmarks Illuminate for World NF Awareness Day as Children's Tumor Foundation Highlights its "Make NF Research Visible" Campaign
The Children's Tumor Foundation (CTF) announces nearly 400 world-famous buildings, bridges, waterfalls, castles and architectural icons are participating in this year's Shine a Light on NF campaign and will show their support in the global fight...

at 08:10
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Guardant Health, Inc. , a leading precision oncology company, today announced that on April 22, 2024, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units ("RSUs") representing 215,601 shares of...

at 08:08
Victoria Eye Center/Victoria Surgery Center/Victoria Vision Center Notice of Data Breach
Victoria Eye Center/Victoria Surgery Center/Victoria Vision Center ("VEC") is writing to provide information regarding an event that involves certain information relating to personal health information.  On March 21, 2024, VEC became aware that...

at 08:05
Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting
Azitra, Inc. , a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced preclinical data from the Company's platform and pipeline. The data are being presented on Friday, May 17,...

at 08:05
Immunome Announces Promotion of Max Rosett to Chief Financial Officer
Immunome, Inc. , a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Mr. Rosett most recently held the role...

at 08:05
Arcadia Biosciences (RKDA) To Host Investor Call To Discuss Recent Transactions
Arcadia Biosciences, Inc.® , a producer and marketer of innovative, plant-based health and wellness products, today announced that it will host a call for analysts and investors after market close on May 22, 2024. The company has scheduled a...

More news about Health...


News published on and distributed by: